AB0377

ARE CO-MORBIDITIES DURING RHEUMATOID ARTHRITIS DIFFERENT FROM THOSE IN ANKYLOSING SPONDYLOARTHRITIS ?

M.A. El Achek, on behalf of Jguirim.M, Farhat.A, Braham.M, Bejjia.I, Touzi.M, Zrour. S, Bergaoui.N. *Rheumatology, Fattouma Bourguiba Hospital, Monastir, Tunisia*

Background: Patients with inflammatory rheumatic diseases are certainly not unscathed from a lot of comorbidities which may be due to the systemic inflammatory activity of rheumatic diseases themselves, immune dysfunction, or iatrogenic, they may also occur independently.

Cardiovascular morbidity remains one of the most important to detect and is increased during these diseases.

So are there significant differences between co-morbidities associated with rheumatoid arthritis (RA) and those with ankylosing spondylarthritis (AS)?

Objectives: To highlight the difference between comorbidities in RA and AS.

Methods: This is a retrospective study of 111 patients followed for RA ACR 1987 criteria, and 60 patients followed for AS, compiled between January 2005 and December 2016.

Results: The mean age of patients with RA was 51.04 years [18–80 years] with a sex ratio (M/F) of 0.18. The average duration of disease progression was 6.54 years [0–29 years]. The mean age of patients with AS was 40.4 years [18–61] with a sex ratio (M/F) of 19. The average duration of disease progression was 16.8 years [1–45 years].

About cardiovascular comorbidities, 16.2% of patients with RA and 5.1% with AS were diagnosed with high blood pressure. Dyslipidemia was found in 2.7% of patients with RA and in 0% with AS.

31.5% with RA and 21.7% of AS have overweight and obesity was illustrated in 22.5% of RA and 11.7% of AS.

Heart and coronary failure were documented in 5.4% of RA and 1.7% of AS. Likewise renal failure in 3.6% of RA and 3.4% of AS. Diabetes was found in 18% of RA and 10% of AS. Hypothyroidism in 5.4% of RA and 1.7% of AS. Gout attack in 0.9% of RA and 0% with AS and osteoporosis in 21.3% of RA and 40% of AS.

Conclusions: Our study concluded at the frequency of comorbidities and mostly cardiovascular in rheumatoid arthritis compared with AS. Osteoporosis is also more common in our studied population with RA, although not rare with our patients with AS. This can be explained by the prescription of corticosteroid therapy in RA.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5788

AB0378

PULMONARY AFFECTION IN EGYPTIAN PATIENTS WITH RHEUMATOID ARTHRITIS

M.S. Abdel-Baky¹, D.F. Mohamed¹, S.H. Hamza¹, D.A. El Sherbiny¹, M. Rezk¹, A. A. Gomaa². ¹Department of Medicine Division of Rheumatology; ²Department of Chest diseases, Ain Shams University, Cairo, Egypt

Background: Rheumatoid arthritis(RA) is a disabling autoimmune systemic inflammatory disease. It manifests as peripheral symmetric inflammatory polyarthritis and produces a wide range of extra-articular manifestations. Interstitial lung disease (ILD), a diffuse progressive disease of the lung parenchyma, is the most serious manifestation of RA lung affection, it remains as a significant source of morbidity and mortality.

Objectives: To evaluate the frequency and pattern of pulmonary affection in a cohort of Egyptian rheumatoid arthritis (RA) patients and the relation to disease activity and severity.

Methods: Seventy RA patients who fulfilled 2010 (ACR/EULAR) classification criteria underwent full clinical assessment, plain X ray chest, chest high-resolution computed tomography (HRCT) with assessment of the extent and severity of pulmonary affection by Warrick score. Pulmonary function tests (PFTs) including diffusion lung capacity for carbon monoxide (DLCO) were done. Transthoracic echocardiography to screen for pulmonary hypertension (PH). Assessment of disease activity by DAS28 score and of radiographic joint damage by modified Larsen score.

Results: The mean age of the patients was 44±10.8 years; females(87.1%) and males (12.9%), mean disease duration 7.3±6 years. PFTs were abnormal in (45.7%) with restrictive pattern in (24.3%) of patients followed by small airway affection in (10%), mixed pattern in (8.6%), the least is the obstructive pattern in (2.8%) of patients. DLCO was abnormal in (72.86%) with mild affection in (48.57%), moderate in (15.7%) and severe affection in (8.6%) of patients. HRCT abnormalities were found in 30 patients (42.85%). Interstitial abnormalities were detected in (35.7%). Septal or reticular lines, ground glass appearance, pleural irregularities and bronchiectasis were the most common findings. Most common HRCT pattern was nonspecific interstitial pneumonia (NSIP) in 12.8% (9/70), usual interstitial pneumonia (UIP) in 7% (5/70), organising pneumonia (OP) in 1.4% (1/70) and indeterminate subtype in 14% (10/70). HRCT total score (Warrick score) was correlated with age, disease activity (DAS ESR 28), ESR, modified Larsen score, FVC, FEV1 and DLCO. Age, dyspnea and DLCO impairment were

significant predictors for development of HRCT chest abnormalities. Pulmonary hypertension(sPAP >30 mmHg) was detected in (14%) of patients.

Conclusions: Pulmonary abnormalities are common in Egyptian RA patients. HRCT and PFTs including DLCO can be used effectively for early diagnosis and monitoring of pulmonary affection in RA patients. DLCO can detect pulmonary abnormalities early in clinically asymptomatic patients. Age, disease activity and severity, PFTs and ESR are correlated with the pulmonary affection in RA. Age, dyspnea and DLCO impairment are significant predictors of pulmonary affection in RA patients. Echocardiography can be used as a screening tool for detection of pulmonary hypertension.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3235

AB0379

MUSCULOSKELETAL INVOLVEMENTS IN GIANT CELL ARTERITIS

M. Tougorti, T. Ben Salem, M.S. Hamdi, M. Lamloum, I. Ben Ghorbel, M. H. Houman. *Internal medicine, RABTA HOSPITAL, Tunis, Tunisia*

Background: Joint involvement is frequent in Giant cell arteritis (GCA), mostly polymyalgia rheumatica (PMR). The aim of this study was to describe clinical features of joint involvement in GCA.

Objectives: To compare patients according to the presence or not of PMR.

Methods: A retrospective and descriptive study of 96 patients with GCA diagnosed between 2000 and 2015. ACR 1990 criteria were used for the diagnosis of GCA. Clinical, biological and histological features were recorded and analysed.

Results: Joint involvements were noted in 67 patients with GCA (69.8%); 34 women and 33 men. Mean age at diagnosis was 72.4±6.36 years. PMR was diagnosed in 45 patients (46.8%) and revealed the disease in two patients. Neck pain was noted in 48 patients. Twenty one patients (21.8%) complained of peripheral arthralgias which revealed GCA in five cases. Joint manifestations were associated to cardinal symptoms of GCA: headache (97%), jaw claudication (62%), scalp tenderness (49.3%) and ophthalmologic manifestations (36.9%). Erythrocyte sediment rate and C-reactive protein were high in 89.2% and 82.7% of cases respectively.

Constitutional symptoms (60% vs 39.2%; p=0.042), jaw claudication (68.2% vs 47.1%; p=0.038) and neck pain (62.2% vs 39.2%; p=0.024) were significantly more frequent in patients with PMR. Peripheral arthralgias (28.9% vs 15.7%) were more frequent in patients with PMR without significant differences. Giant cell vasculitis on temporal arterial biopsy was more frequent in patients with PMR (57% vs 30%; p=0.037).

Corticosteroids were given in 97% of patients while methotrexate was used in 20.9%.

Conclusions: PMR in patients with GCA seem to be associated to different joint manifestations.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3798

AB0380

DELAY IN TIME TO DIAGNOSIS INCREASES THE RISK OF SUFFERING CLASSIC CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Robustillo Villarino¹, A. Sendra García², J.J. Alegre Sancho¹. ¹Rheumatology, Hospital Universitari Dr Peset i Aleixandre; ²Rheumatology, Foundation for the Promotion of Health and Biomedical Research of Valencia (FISABIO), Valencia, Spain

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that constitutes an independent cardiovascular risk factor (CVRF). In addition, patients with RA have a higher prevalence of CVRF than the general population.

Objectives: To assess whether delay in time to diagnosis of the disease may increase the risk of CVRF in patients with RA.

Methods: Patients diagnosed with RA, according to the EULAR/ACR 2010 classification criteria, were consecutively selected and recruited for a period of 12 months. Delay in time to diagnosis was calculated as the interval between the beginning of first joint symptoms and the diagnosis of RA with start of specific treatment. Furthermore, the presence or absence of arterial hypertension (AHT), dyslipidemia (DL) and diabetes mellitus (DM) were recorded. Whether its diagnosis was prior or subsequent to the diagnosis of the inflammatory disease was also recorded. SPSS version 17.0 software was used for statistical analysis, considering statistical significance for p<0.05.

Results: A total of 244 patients were studied, 73.8% (180) of whom were women and 26.2% (64) men. The mean age was 60.42 years (SD 13.24). Mean Delay in time to diagnosis was 2.1 years (SD 5.5). Mean age at diagnosis was 48.9 years (SD 15.7). Regarding classic CVRF, the percentage of patients with AHT, DL and DM before RA diagnosis were 17.6% (43), 6.1% (15) and 6.1% (15), respectively.